Cytori Therape…
ProfileJobs

Cytori Therapeutics

Suggest Edit
    • Healthbiotechdrug developmenthealthtechlife sciencesmedical devicesmedtechoncologypharmatherapy

    Cytori Therapeutics develops cellular therapeutics for specific diseases and medical conditions. The Company primarily provides Cytori Cell Therapy for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets, and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The Company also provides a number of products for use in treating various cancers.

    Market capitalization(2018-07-11)
    $770.3 K
    Type
    Public
    HQ
    San Diego, US
    Founded
    2002
    Size (employees)
    80 (est)
    Website
    cytori.com
    Cytori Therapeutics was founded in 2002 and is headquartered in San Diego, US
    Report incorrect company information

    Cytori Therapeutics Office Locations

    Cytori Therapeutics has offices in Deeside, San Antonio, San Diego and Tokyo
    San Diego, US (HQ)
    3020 Callan Road
    San Antonio, US
    12500 Network Blvd
    Tokyo, JP
    Otemachi Park Building 7F 1-1-1 Otemachi, Chiyoda-ku
    Deeside, GB
    Deeside Industrial Park East Unit 68, Third Avenue
    Show all (4)
    Report incorrect company information

    Cytori Therapeutics Financials and Metrics

    Cytori Therapeutics Revenue

    Cytori Therapeutics's revenue was reported to be $4.66 m in FY, 2016 which is a 3.8% decrease from the previous period.
    USD

    Net income (Q1, 2018)

    		(4.4 m)

    EBIT (Q1, 2018)

    		(4.4 m)

    Market capitalization (11-Jul-2018)

    		770.3 k

    Closing share price (11-Jul-2018)

    		1.3

    Cash (31-Mar-2018)

    		5.9 m
    Cytori Therapeutics's current market capitalization is $770.3 k.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		7.1 m5 m4.8 m4.7 m

    Revenue growth, %

    		(30%)(2%)(4%)

    Cost of goods sold

    		3.4 m2.9 m3.2 m2.7 m

    Gross profit

    		3.7 m2 m1.7 m1.9 m
    Quarterly
    USDQ1, 2018

    Sales and marketing expense

    		678 k

    General and administrative expense

    		2.2 m

    R&D expense

    		2.5 m

    Operating expense total

    		5.4 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		15.5 m14.6 m14.3 m12.6 m9.6 m

    Accounts Receivable

    Inventories

    		3.7 m3.2 m

    Current Assets

    		24.6 m21.7 m21.2 m18.7 m14.9 m
    Quarterly
    USDQ1, 2018

    Cash

    		5.9 m

    Inventories

    		3.2 m

    Current Assets

    		10.7 m

    PP&E

    		2.9 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(26.2 m)(37.4 m)(18.7 m)(22 m)(22.7 m)

    Depreciation and Amortization

    		1.6 m779 k1.1 m1.2 m2.2 m

    Inventories

    		(459 k)(815 k)490 k471 k251 k

    Accounts Payable

    		(409 k)(1.1 m)1 m(673 k)(1.8 m)
    Quarterly
    USDQ1, 2018

    Net Income

    		(4.4 m)

    Depreciation and Amortization

    		497 k

    Inventories

    		141 k

    Accounts Payable

    		(556 k)
    show all
    USDY, 2018

    Financial Leverage

    		3.1 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    ImmunoCellular Therapeutics
    Health - Public
    Seres Therapeutics
    Health - Public
    Achieve Life Sciences
    Health - Public
    Anavex
    Health - Public
    Compare competitors

    Cytori Therapeutics Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Cytori Therapeutics News and Updates

    May 11, 2018

    Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript

    Report incorrect company information

    Cytori Therapeutics Company Life and Culture

    Report incorrect company information
    Download PDF